Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer

Cancer Prev Res (Phila). 2023 Jan 4;16(1):47-55. doi: 10.1158/1940-6207.CAPR-22-0210.

Abstract

Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. This phase I study evaluates topical bexarotene, as a potential chemoprevention agent, for safety and toxicity in high-risk women for breast cancer.

Trial registration: ClinicalTrials.gov NCT02876640.

Publication types

  • Clinical Trial, Phase I
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Bexarotene* / administration & dosage
  • Bexarotene* / adverse effects
  • Female
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Bexarotene
  • Antineoplastic Agents

Associated data

  • ClinicalTrials.gov/NCT02876640